从renin-angiotensin-aldosterone系统对前列腺癌的新见解
Yashvi Patel1, Payal Thapa1, Akhilesh Prajapati1
1Life Science Department, School of Science, GSFC University, Vadodara 391750, India.
Cellular signalling
|October 5, 2024
概括
氨酸-氨酸-阿尔多斯特系统 (RAAS) 在前列腺癌的进展中起着关键作用,影响细胞生长和转移. 针对RAAS组件为这种常见的男性恶性瘤提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 前列腺癌是一种流行的男性恶性瘤,具有复杂的病理生理学.
- 雷宁-氨-阿尔多斯特系统 (RAAS) 越来越多地被认为在癌症生物学中的作用.
- RAAS的组成部分影响关键的癌症过程,如细胞生长,迁移和转移.
研究的目的:
- 探索RAAS在前列腺癌发展和进展中的多方面的作用.
- 确定RAAS组件作为前列腺癌的潜在治疗点.
- 了解RAAS失调如何导致前列腺癌的病理生理学.
主要方法:
- 审查关于RAAS和前列腺癌的现有文献.
- 分析RAAS途径的组成部分 (例如,前林因,AT1R,AT2R,Ang 1-7/Mas受体).
- 研究RAAS对关键信号通路 (AR,NF-κB,PI3K/AKT/mTOR) 的影响.
主要成果:
- RAAS的成分显著影响前列腺癌细胞生长,血管新生和转移.
- 通过AT1R促进癌症进展,而AT2R和ACE2/Ang1-7/Mas途径显示抑制作用.
- RAAS与像雄激素受体 (AR) 这样的关键信号通路相互作用,影响前列腺癌.
结论:
- RAAS的失调与前列腺癌的进展有关.
- 针对RAAS,包括其与心血管疾病相关的途径,是一个可行的治疗途径.
- 了解RAAS信号提供了前列腺癌干预的新策略.
更多相关视频
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
4.7K
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
506
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
506
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
01:33Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
01:29Hypertension II: Pathophysiology
2
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
2
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
597
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
597
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395